Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Alvotech’s Deal with Regeneron, Bayer Clears Way for Eylea Biosimilar in Multiple Markets
Alvotech, of Reykjavik, Iceland, reported Jan. 29 that it had reached a settlement and license agreement with Regeneron and Bayer that resolves all remaining patent disputes worldwide for its biosi...
Quarterly and 2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Novartis, and Astellas
Swiss company Roche reported Jan. 29 that global sales of Vabysmo for 2025 were CHF 4.1 billion ($5.2 billion, converted Dec. 25, 2025), a 6 percent increase on a reported basis (+12 percent cc) ov...
Sandoz Launches Aflibercept Biosimilar Enzeevu in Canada
Swiss drugmaker Sandoz announced Feb. 2 that it had launched its Eylea biosimilar, branded Enzeevu, in Canada. Enzeevu (aflibercept-abzv) gained approval in Canada in October 2025 for all the refer...
STAAR Names Warren Foust and Deborah Andrews as Interim Co-CEOs Amid Search for Permanent Leader
STAAR Surgical, of Lake Forest, California, reported Feb. 2 that it had appointed Warren Foust and Deborah Andrews as interim co-CEOs, while the company conducts a global search for a permanent CEO...
Harrow Ends Compounded Product Sales in California, Plans to Sell All Products Under Harrow Label
Harrow reported Feb. 2 that it had stopped selling compounded products in California through its ImprimisRx subsidiary on Feb. 1, after settling a disciplinary action brought by the California Boar...
US FDA Gives Green Light to Trial of Life Bio’s Cell Rejuvenation Candidate in Optic Neuropathies
Life Biosciences reported on Jan. 28 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I trial of ER-100, a cell rejuven...
Santen Gains Approval in Japan for RVL’s Blepharoptosis Drops Under Name Upneeq Mini
RVL Pharmaceuticals announced Jan. 8 that its partner Santen had gained manufacturing and marketing approval in Japan for RVL’s eye drop formulation of oxymetazoline hydrochloride, to be known in J...
Opus Launches Trial in Abu Dhabi for RP Gene Therapy Candidate
Opus Genetics announced Jan. 27 that it had launched a clinical trial in Abu Dhabi, the capital of the United Arab Emirates, for its gene therapy candidate targeting MERTK-related retinitis pigment...
Merged Southeastern US Eye Banks Will Be Known as Precision Ocular Network
Two Southeastern US eye banks, Advancing Sight Network and Miracles In Sight, announced Jan. 27 that their merged operations would be known as Precision Ocular Network. The organizations announced ...
US FDA Grants Orphan Drug Status to BlueRock’s RP Cell Therapy Candidate
Bayer subsidiary BlueRock Therapeutics announced Jan. 22 that the US FDA had granted orphan drug status to OpCT-001, its cell therapy candidate for retinitis pigmentosa (RP). Orphan drug designatio...
US FDA Grants Fast Track Status to Drug Farm’s ROSAH Candidate
Drug Farm, of Shanghai, China, announced Jan. 27 that the US FDA had granted fast track designation to DF-003, an oral alpha kinase 1 (ALPK1) inhibitor targeting the rare genetic disease ROSAH synd...
Orbis International Appoints Kathleen Sherwin, MBA, as President and CEO
Orbis International announced Jan. 12 that it had appointed Kathleen Sherwin as president and chief executive officer. New York-based Orbis said Sherwin brings more than 25 years of experience adva...
Past News Stories
US FDA Approves Re-administration of Glaukos’ iDose TR
Glaukos announced Jan. 28 that the US FDA had approved a supplement to its new drug application allowing for re-administration of iDose TR, the company’s intracameral travoprost implant for glaucom...
US FDA Approves Tenpoint’s Yuvezzi Drops for Presbyopia
Tenpoint Therapeutics announced Jan. 28 that the US FDA had approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for presbyopia. The company said it expects to launc...
EU-India Free Trade Agreement to Phase in Lower Pharma and Device Tariffs
A free trade agreement reached Jan. 27 by the European Union and India will reduce or eliminate tariffs on about 90 percent of goods, including pharmaceuticals and medical devices, between the two ...
US FDA Rolls Out PreCheck Program to Speed Approval of Drug Manufacturing Plants
The US FDA announced Jan. 21 that it would begin accepting applications on Feb. 1, 2026, for its new PreCheck Pilot Program to improve the regulatory process for US manufacturing facilities. The ag...
Nidek Launches the Phantom Open-Field Refraction System
Japanese company Nidek reported Jan. 26 that it had launched the Phantom Open-Field Refractive System. An open-field system eliminates the traditional phoropter in front of the patient; instead, vi...
US FDA Gives Green Light to Phase II Trial of Novaliq’s Topical Uveitis Candidate
Germany’s Novaliq reported on Jan. 26 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II trial of NOV05, its topical, ...
US FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain
London’s Okyo Pharma announced Jan. 23 that the US FDA had authorized a compassionate-use request for a single patient with severe neuropathic corneal pain to be treated with urcosimod (0.05%). The...
Emmecell Appoints Ramin Valian as Chief Executive Officer
Emmecell announced Jan. 16 that it had appointed ophthalmic industry veteran Ramin Valian as chief executive officer. Valian spent more than 20 years in top roles at Allergan and AbbVie, where he d...
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
J&J Vision Reports 2025 Surgical Vision Revenue of $1.6 Billion
Johnson & Johnson reported Jan. 21 that its full year 2025 global surgical vision revenue was $1.6 billion, a 10.2 percent increase over $1.4 billion in 2024. Revenue was up 6.1 percent in the US a...
Rayner Launches Sophi Phaco Machine in the US
UK-based Rayner reported Jan. 14 that it was launching its Sophi phacoemulsification system in the US. The unit, whose name is short for Swiss ophthalmology innovation, was developed by Swiss firm ...
Eylea 8 mg Gains EU Approval to Treat Macular Edema Following RVO
German drugmaker Bayer announced Jan. 16 that the European Commission had approved Eylea 8 mg, known as Eylea HD in the US, to treat patients with visual impairment due to macular edema following r...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.